SecBot SecBot
PRESS-RELEASE ·Filed May 14, 2026

EDAP

EDAP TMS S.A.
NEUTRAL
Impact 3/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · Contract
Actionable Insight • Neutral

This is an early-stage exploratory collaboration with no binding commitments. Traders should watch for definitive agreements, clinical data, or commercial milestones. The lack of financial terms and the non-binding nature limit near-term stock impact. Monitor for further press releases or regulatory filings (e.g., 8-K) if definitive agreements are reached.

DirectionNeutral
Confidencemedium
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$4.13
T+0 close · May 14, 2026 · via day close
Latest settled
+15.50%
T+20 · $4.77
Vs SPY
+16.35%
α at T+20
Next horizon
T+60
due 3mo ago
  1. T+0 · May 14 $4.13entry
  2. T+1 · 6mo ago +1.57%α +2.80% · $4.20
  3. T+5 · 6mo ago +4.84%α +5.56% · $4.33
  4. T+20 · 5mo ago +15.50%α +16.35% · $4.77
  5. T+60 · due 3mo ago Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

EDAP TMS announced a non-binding letter of intent with Telix Pharmaceuticals to explore joint clinical research and physician education combining Focal One Robotic HIFU with Telix's PSMA PET imaging for prostate cancer. The LOI imposes no financial commitments and is not expected to have a material impact on EDAP's financial results. The collaboration is exploratory at this stage.

Key Facts

  • Non-binding LOI with Telix to explore combination of Focal One HIFU and PSMA PET imaging in prostate cancer
  • Initial focus on treatment planning, image-guided therapy, and post-treatment monitoring
  • No financial commitments or material financial impact expected
  • No definitive agreements have been signed; no assurance any specific initiatives will result

Financial Impact

No financial terms disclosed; not expected to be material

revenue

Risk Factors

  • No guarantee definitive agreements will be signed
  • Collaboration may not lead to commercial products or revenue
  • Potential dilution or R&D costs if future milestones are pursued

Market Snapshot

Exchange
Nasdaq
Sector
Electromedical & Electrotherapeutic Apparatus
Analyst Consensus
67% bullish (9 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3294789

Track record

12 reports on EDAP

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Aug 17, 202613w ago Insider Cluster Mixed 5/10 No price data
  2. May 29, 202624w ago 8-K Neutral 4/10 Entry $4.32 to $5.10 ▲ +18.06% +19.85% vs SPY
  3. May 14, 202626w ago DEFA14A Bearish 6/10 Entry $4.13 to $4.77 ▼ −15.50% −16.35% vs SPY
  4. May 14, 202626w ago DEFA14A Neutral 3/10 Entry $4.13 to $4.77 ▲ +15.50% +16.35% vs SPY
  5. May 14, 202626w ago Press Release Neutral 3/10 Viewing Entry $4.13 to $4.77 ▲ +15.50% +16.35% vs SPY
  6. May 7, 202627w ago 8-K Mixed 6/10 Entry $4.16 to $4.69 ▲ +12.74% +9.60% vs SPY
  7. Apr 16, 202630w ago Press Release Neutral 1/10 Entry $3.59 to $4.16 ▲ +15.88% +10.06% vs SPY
  8. Apr 1, 202632w ago EFFECT Neutral 4/10 Entry $3.53 to $3.31 ▼ −6.23% −15.95% vs SPY
  9. Mar 26, 202633w ago S-3/A Neutral 4/10 Entry $3.73 to $3.22 ▼ −13.67% −26.41% vs SPY
  10. Mar 25, 202633w ago S-3 Neutral 5/10 Entry $3.77 to $3.22 ▼ −14.59% −25.25% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens Wed (9h 59m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 14, 2026